Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms
Abstract Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects approximately 0.46% of the global population. Conventional therapeutics for RA, including disease‐modifying antirheumatic drugs (DMARDs), nonsteroidal anti‐inflammatory drugs (NSAIDs), and corticosteroids, frequently res...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Animal Models and Experimental Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ame2.12518 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087814044385280 |
|---|---|
| author | Mohammad Yasin Zamanian Hamidreza Zafari Maria K. Osminina Alla A. Skakodub Raed Fanoukh Aboqader Al‐Aouadi Maryam Golmohammadi Nikta Nikbakht Iman Fatemi |
| author_facet | Mohammad Yasin Zamanian Hamidreza Zafari Maria K. Osminina Alla A. Skakodub Raed Fanoukh Aboqader Al‐Aouadi Maryam Golmohammadi Nikta Nikbakht Iman Fatemi |
| author_sort | Mohammad Yasin Zamanian |
| collection | DOAJ |
| description | Abstract Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects approximately 0.46% of the global population. Conventional therapeutics for RA, including disease‐modifying antirheumatic drugs (DMARDs), nonsteroidal anti‐inflammatory drugs (NSAIDs), and corticosteroids, frequently result in unintended adverse effects. Dexamethasone (DEX) is a potent glucocorticoid used to treat RA due to its anti‐inflammatory and immunosuppressive properties. Liposomal delivery of DEX, particularly when liposomes are surface‐modified with targeting ligands like peptides or sialic acid, can improve drug efficacy by enhancing its distribution to inflamed joints and minimizing toxicity. This study investigates the potential of liposomal drug delivery systems to enhance the efficacy and targeting of DEX in the treatment of RA. Results from various studies demonstrate that liposomal DEX significantly inhibits arthritis progression in animal models, reduces joint inflammation and damage, and alleviates cartilage destruction compared to free DEX. The liposomal formulation also shows better hemocompatibility, fewer adverse effects on body weight and immune organ index, and a longer circulation time with higher bioavailability. The anti‐inflammatory mechanism is associated with the downregulation of pro‐inflammatory cytokines like tumor necrosis factor‐α (TNF‐α) and B‐cell–activating factor (BAFF), which are key players in the pathogenesis of RA. Additionally, liposomal DEX can induce the expression of anti‐inflammatory cytokines like interleukin‐10 (IL‐10), which has significant anti‐inflammatory and immunoregulatory properties. The findings suggest that liposomal DEX represents a promising candidate for effective and safe RA therapy, with the potential to improve the management of this debilitating disease by providing targeted delivery and sustained release of the drug. |
| format | Article |
| id | doaj-art-ab1a5371baa64f968d479fd2e1764a29 |
| institution | Kabale University |
| issn | 2576-2095 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Animal Models and Experimental Medicine |
| spelling | doaj-art-ab1a5371baa64f968d479fd2e1764a292025-02-06T03:52:55ZengWileyAnimal Models and Experimental Medicine2576-20952025-01-018151910.1002/ame2.12518Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanismsMohammad Yasin Zamanian0Hamidreza Zafari1Maria K. Osminina2Alla A. Skakodub3Raed Fanoukh Aboqader Al‐Aouadi4Maryam Golmohammadi5Nikta Nikbakht6Iman Fatemi7Department of Physiology, School of Medicine Hamadan University of Medical Sciences Hamadan IranDepartment of Orthopedic Surgery, Joint Reconstruction Research Center, Imam Khomeini Hospital Complex, School of Medicine Tehran University of Medical Sciences Tehran IranPediatric department I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University) Moscow Russian FederationDepartment of Pediatric Preventive Dentistry E.V. Borovsky I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University) Moscow Russian FederationDepartment of Medicine, College of Medicine Al‐Ayen Iraqi University Thi‐Qar IraqSchool of Medicine Shahid Beheshti University of Medical Sciences Tehran IranDepartment of Physical Medicine and Rehabilitation, School of Pharmacy Hamadan University of Medical Sciences Hamadan IranResearch Center of Tropical and Infectious Diseases Kerman University of Medical Sciences Kerman IranAbstract Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects approximately 0.46% of the global population. Conventional therapeutics for RA, including disease‐modifying antirheumatic drugs (DMARDs), nonsteroidal anti‐inflammatory drugs (NSAIDs), and corticosteroids, frequently result in unintended adverse effects. Dexamethasone (DEX) is a potent glucocorticoid used to treat RA due to its anti‐inflammatory and immunosuppressive properties. Liposomal delivery of DEX, particularly when liposomes are surface‐modified with targeting ligands like peptides or sialic acid, can improve drug efficacy by enhancing its distribution to inflamed joints and minimizing toxicity. This study investigates the potential of liposomal drug delivery systems to enhance the efficacy and targeting of DEX in the treatment of RA. Results from various studies demonstrate that liposomal DEX significantly inhibits arthritis progression in animal models, reduces joint inflammation and damage, and alleviates cartilage destruction compared to free DEX. The liposomal formulation also shows better hemocompatibility, fewer adverse effects on body weight and immune organ index, and a longer circulation time with higher bioavailability. The anti‐inflammatory mechanism is associated with the downregulation of pro‐inflammatory cytokines like tumor necrosis factor‐α (TNF‐α) and B‐cell–activating factor (BAFF), which are key players in the pathogenesis of RA. Additionally, liposomal DEX can induce the expression of anti‐inflammatory cytokines like interleukin‐10 (IL‐10), which has significant anti‐inflammatory and immunoregulatory properties. The findings suggest that liposomal DEX represents a promising candidate for effective and safe RA therapy, with the potential to improve the management of this debilitating disease by providing targeted delivery and sustained release of the drug.https://doi.org/10.1002/ame2.12518dexamethasoneinflammationliposomerheumatoid arthritisTNF‐α |
| spellingShingle | Mohammad Yasin Zamanian Hamidreza Zafari Maria K. Osminina Alla A. Skakodub Raed Fanoukh Aboqader Al‐Aouadi Maryam Golmohammadi Nikta Nikbakht Iman Fatemi Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms Animal Models and Experimental Medicine dexamethasone inflammation liposome rheumatoid arthritis TNF‐α |
| title | Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms |
| title_full | Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms |
| title_fullStr | Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms |
| title_full_unstemmed | Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms |
| title_short | Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms |
| title_sort | improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome focusing on inflammation and molecular mechanisms |
| topic | dexamethasone inflammation liposome rheumatoid arthritis TNF‐α |
| url | https://doi.org/10.1002/ame2.12518 |
| work_keys_str_mv | AT mohammadyasinzamanian improvingdexamethasonedrugloadingandefficacyintreatingrheumatoidarthritisvialiposomefocusingoninflammationandmolecularmechanisms AT hamidrezazafari improvingdexamethasonedrugloadingandefficacyintreatingrheumatoidarthritisvialiposomefocusingoninflammationandmolecularmechanisms AT mariakosminina improvingdexamethasonedrugloadingandefficacyintreatingrheumatoidarthritisvialiposomefocusingoninflammationandmolecularmechanisms AT allaaskakodub improvingdexamethasonedrugloadingandefficacyintreatingrheumatoidarthritisvialiposomefocusingoninflammationandmolecularmechanisms AT raedfanoukhaboqaderalaouadi improvingdexamethasonedrugloadingandefficacyintreatingrheumatoidarthritisvialiposomefocusingoninflammationandmolecularmechanisms AT maryamgolmohammadi improvingdexamethasonedrugloadingandefficacyintreatingrheumatoidarthritisvialiposomefocusingoninflammationandmolecularmechanisms AT niktanikbakht improvingdexamethasonedrugloadingandefficacyintreatingrheumatoidarthritisvialiposomefocusingoninflammationandmolecularmechanisms AT imanfatemi improvingdexamethasonedrugloadingandefficacyintreatingrheumatoidarthritisvialiposomefocusingoninflammationandmolecularmechanisms |